Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 474

Sort by

Sort Order Select

Journal Articles

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Nadine Vollack-Hesse, Olga Oleshko, Sonja Werwitzke, Barbara Solecka-Witulska, Christoph Kannicht, Andreas Tiede

Blood (2021) 137 (8): 1072–1081.

https://doi.org/10.1182/blood.2020006468

Published: 2021

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

Shuchi Gulati, MD, Zizi Elsisi, Smruti Deoghare, Mark Eckman

Blood (2019) 134 (Supplement_1): 328.

https://doi.org/10.1182/blood-2019-124756

Published: 2019

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

https://doi.org/10.1182/blood-2019-122350

Published: 2019

Journal Articles

The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study

Li Yang, Ligen Liu, Limin Zhao, Yingting Lu, Jing Zhang, Lihua Sun

Blood (2019) 134 (Supplement_1): 5108.

https://doi.org/10.1182/blood-2019-131671

Published: 2019

Journal Articles

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Jiliang Xia, PhD, Yanjuan He, MD, Bin Meng, Jingyu Zhang, Xuan Wu, Xiangling Feng, PhD, Chunmei Kuang, Jiaojiao Guo, Yinghong Zhu, Qian Lei, Yongjun Guan, Yi Shen, MD PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 4332.

https://doi.org/10.1182/blood-2019-126617

Published: 2019

Journal Articles

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5142.

https://doi.org/10.1182/blood-2019-127143

Published: 2019

Journal Articles

The Safety of Novel Drugs Targeting Factor XI and XII in Human Clinical Trials:a Systematic Review

Gillian E Mair, Sven Reid Olson, MD, Joseph J Shatzel, MD

Blood (2019) 134 (Supplement_1): 4966.

https://doi.org/10.1182/blood-2019-130823

Published: 2019

Journal Articles

Combination of Interferon α, Delivered By Engineered Mesenchymal Stromal Cells, and Cytarabine Limits the Development of Acute Myeloid Leukemia, Potentially Targeting Leukemic Stem Cells

Desbourdes M. Laura, PhD, Suheyla Hasgur, DVM, PhD, Adam J Guess, Minjun Yu, PhD, Satoru Otsuru, MD PhD, Edwin M. Horwitz, MD PhD

Blood (2019) 134 (Supplement_1): 5143.

https://doi.org/10.1182/blood-2019-127456

Published: 2019

Journal Articles

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Gaetano Giuffrida, MD, Concetta Conticello, MD, Valeria Calafiore, Enrica Antonia Martino, MD, Silvia Giamporcaro, MD, Alessandra Romano, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4972.

https://doi.org/10.1182/blood-2019-131015

Published: 2019

Journal Articles

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier, Florence Rabian, MD, Hélène Boutroux, MD, Marion Strullu, MD, Karine Morand, MD, Florian Chevillon, MD, Benoit Brethon, MD, Nicolas Boissel, MD PhD, Guy Leverger, MD, André Baruchel, MD

Blood (2019) 134 (Supplement_1): 5130.

https://doi.org/10.1182/blood-2019-131062

Published: 2019

Journal Articles

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

Po Hu, Hui Li, Bao-An Chen, Hua Tang, Zheng Ge, MD PhD, Jing Zhang, Hui Hui, Qing-long Guo

Blood (2019) 134 (Supplement_1): 5756.

https://doi.org/10.1182/blood-2019-122409

Published: 2019

Journal Articles

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Rodney H Falk, MD, Morie A Gertz, MD, Merrill D Benson, MD, Gustavo Buchele, MD PhD, Michela Brambatti, MD MS, Sotirios Tsimikas, MD, Nicholas J Viney, Bsc, Li-Jung Tai, MD PhD, Cecilia Monteiro, MD PhD, Qingqing Yang, MS, Louis St L O'Dea, MB B.Ch. BAO, FRCP, Ewa Karwatowska-Prokopczuk, MD PhD, Eugene Schneider, MD, Richard S Geary, PhD, Brett P Monia, PhD

Blood (2019) 134 (Supplement_1): 5764.

https://doi.org/10.1182/blood-2019-129269

Published: 2019

Journal Articles

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Susan U Lattimore, Madolyn T Hofstetter, BS

Blood (2019) 134 (Supplement_1): 5796.

https://doi.org/10.1182/blood-2019-131030

Published: 2019

Journal Articles

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

Hanny Al-Samkari, MD, Stacy E. Croteau

Blood (2019) 134 (Supplement_1): 3395.

https://doi.org/10.1182/blood-2019-125364

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

Tinghua Zhang, Yinghua Xie, Limin Zhao, Xiyao Han, Yingting Lu, Jing Zhang, Yanhui Xie, Qi Zhu, Lihua Sun, Li Yang, Ligen Liu

Blood (2019) 134 (Supplement_1): 3843.

https://doi.org/10.1182/blood-2019-125739

Published: 2019

Journal Articles

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Ruihua Mi, Lin Chen, MD, Xudong Wei, PhD, Xiaojiao WANG, Yongping Song, MD

Blood (2019) 134 (Supplement_1): 3865.

https://doi.org/10.1182/blood-2019-128431

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

NARROW

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

A complementary new drug for PNH

Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

The Safety of Novel Drugs Targeting Factor XI and XII in Human Clinical Trials:a Systematic Review

Combination of Interferon α, Delivered By Engineered Mesenchymal Stromal Cells, and Cytarabine Limits the Development of Acute Myeloid Leukemia, Potentially Targeting Leukemic Stem Cells

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only